FDA notifications.  Combination lamivudine and tenofovir tablet approved.
D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004338:Drug Combinations; D015658:HIV Infections / Q000188:drug therapy*; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D013607:Tablets; D014481:United States; D014486:United States Food and Drug Administration
D004338:Drug Combinations; D018894:Reverse Transcriptase Inhibitors; D013607:Tablets; D019259:Lamivudine